The summaries of product characteristics (SPC) contain the information relevant to the use of the medicinal products and of importance to health care professionals. The SPCs are published in Finnish; the use of Finnish key words in the search fields is therefore recommended.
Some of the medicinal products contain a condition relevant to the prescribing of the product and not always found in the SPC. The conditions for prescribing and the products covered by this condition are found in the FimeaWeb search.
The SPCs processed as part of the EU centralised marketing authorisation procedure are published by the European Medicines Agency, EMA. Fimea's service contains links to the documents on medicinal products (EPAR PI) on the EMA website. Drugs belonging to the centralised authorisation procedure can be searched in Fimea's service by using an alphabetical list or by entering the product name or ATC code.
The material being published is not necessarily complete or up-to-date due to the technical quality of files submitted to the Finnish Medicines Agency Fimea or earlier to the National Agency for Medicines and the delays in delivery. For this reason, Fimea cannot guarantee that the document on the Internet fully complies with the summary of product characteristics and package leaflet officially approved by a desicion for a marketing authorisation. Only the hard copies of the SPCs and the PLs, which are in accordance with the marketing authorisation, are conclusive.
Summaries of Product Characteristics 31 - 60 of 253 |
|
|
Package leaflet | Status for supply | Name of the medicinal product |
|
|
European Medicines Agency's website: Rebif - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Reblozyl - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Recarbrio - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Recikalc-D 500 mg-400 IU tabletti, kalvopäällysteinen SPC 2024-11-13
|
PL
|
Itsehoito
|
Recipect oraaliliuos SPC 2022-06-09
|
PL
|
Itsehoito
|
Recreol 50 mg-g emulsiovoide SPC 2024-01-17
|
PL
|
Itsehoito
|
Recreol 50 mg-g voide SPC 2024-01-17
|
PL
|
Resepti
|
Rectogesic 4 mg-g rektaalivoide SPC 2024-03-15
|
|
|
European Medicines Agency's website: ReFacto AF - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Refixia - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Regiocit hemofiltraationeste SPC 2024-08-01
|
|
|
European Medicines Agency's website: Regkirona - EMA: EPAR PI
Finnish Swedish
|
PL
|
Itsehoito
|
Rehydron Optim jauhe oraaliliuosta varten SPC 2023-06-15
|
|
|
European Medicines Agency's website: Rekambys - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Rekovelle - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Relafalk 200 mg säädellysti vapauttava tabletti SPC 2024-01-29
|
PL
|
Resepti
|
Relenza 5 mg-annos inhalaatiojauhe, annosteltu SPC 2023-12-19
|
PL
|
Resepti
|
Relert 40 mg tabletti, kalvopäällysteinen SPC 2023-11-01
|
PL
|
Resepti
|
Relfydess 100 yksikköä-ml injektioneste, liuos SPC 2024-10-07
|
PL
|
Resepti
|
Relifex 500mg ja 1g tabletti, 1g liukeneva tabletti SPC 2020-10-02
|
|
|
European Medicines Agency's website: Relistor - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Relvar Ellipta - EMA: EPAR PI
Finnish Swedish
|
|
|
European Medicines Agency's website: Remicade - EMA: EPAR PI
Finnish Swedish
|
PL
|
Resepti
|
Remifentanil B. Braun 1 mg, 2 mg, 5 mg kuiva-aine välikonsentraatiksi injektio-infuusionestettä varten, liuos SPC 2022-05-12
|
PL
|
Resepti
|
Remifentanil hameln 1 mg, 2 mg, 5 mg kuiva-aine välikonsentraatiksi injektiö/infuusionestettä varten, liuos SPC 2022-04-21
|
PL
|
Resepti
|
Remifentanil Orion 1 mg, 2 mg, 5 mg kuiva-aine välikonsentraatiksi injektio-infuusionestettä varten, liuos SPC 2023-07-25
|
PL
|
Resepti
|
Reminyl 8 mg + 16 mg depotkapseli, kova SPC 2021-11-15
|
PL
|
Resepti
|
Reminyl 8 mg, 16 mg, 24 mg depotkapseli, kova SPC 2021-11-15
|
PL
|
Resepti
|
Remodulin 1 mg-ml infuusioneste, liuos SPC 2022-03-21
|
PL
|
Resepti
|
Remodulin 10 mg-ml infuusioneste, liuos SPC 2022-03-21
|
|